Search Results - "Hill, Jason E"

Longitudinal Analysis of Neural Network Development in Preterm Infants by Smyser, Christopher D., Inder, Terrie E., Shimony, Joshua S., Hill, Jason E., Degnan, Andrew J., Snyder, Abraham Z., Neil, Jeffrey J.

“…Application of resting state functional connectivity magnetic resonance imaging (fcMRI) to the study of prematurely born infants enables assessment of the…”
Get full text

Small Molecules That Reactivate p53 in Renal Cell Carcinoma Reveal a NF-κB-Dependent Mechanism of p53 Suppression in Tumors by Katerina V. Gurova, Hill, Jason E., Canhui Guo, Anatoly Prokvolit, Burdelya, Lyudmila G., Eugenia Samoylova, Anna V. Khodyakova, Ram Ganapathi, Mahrukh Ganapathi, Natalia D. Tararova, Dmitry Bosykh, Dmitriy Lvovskiy, Thomas R. Webb, Stark, George R., Gudkov, Andrei V.

“…Renal cell carcinomas (RCC) commonly retain wild-type but functionally inactive p53, which is repressed by an unknown dominant mechanism. To help reveal this…”
Get full text

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia by Altman, Jessica K., Perl, Alexander E., Hill, Jason E., Rosales, Matt, Bahceci, Erkut, Levis, Mark J.

“…The FLT3 inhibitor gilteritinib has clinical activity in patients with FLT3‐mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML). The…”
Get full text

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells by Spector, Neil L, Yarden, Yosef, Smith, Bradley, Lyass, Ljuba, Trusk, Patricia, Pry, Karen, Hill, Jason E, Xia, Wenle, Seger, Rony, Bacus, Sarah S

“…The human EGF receptor (HER) 2 receptor tyrosine kinase is a survival factor for human cardiomyocytes, and its inhibition may explain the increased incidence…”
Get full text

p53 pathway in renal cell carcinoma is repressed by a dominant mechanism by GUROVA, Katerina V, HILL, Jason E, RAZORENOVA, Olga V, CHUMAKOV, Peter M, GUDKOV, Andrei V

“…Renal cell carcinoma (RCC) rarely acquires mutations in p53 tumor suppressor gene, suggesting that p53 signaling in this tumor type might be repressed by some…”
Get full text

Down-Regulation of p53 by Double-Stranded RNA Modulates the Antiviral Response by MARQUES, Joao T, REBOUILLAT, Dominique, RAMANA, Chilakamarti V, MURAKAMI, Junko, HILL, Jason E, GUDKOV, Andrei, SILVERMAN, Robert H, STARK, George R, WILLIAMS, Brvan R. G

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib by Smith, Catherine C., Levis, Mark J., Perl, Alexander E., Hill, Jason E., Rosales, Matt, Bahceci, Erkut

“…The phase 3 Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase…”
Get full text

PCR-Based Subtractive Hybridization and Differences in Gene Content among Strains of Helicobacter pylori by Akopyants, Natalia S., Fradkov, Arkady, Diatchenko, Luda, Hill, Jason E., Siebert, Paul D., Lukyanov, Sergey A., Sverdlov, Eugene D., Berg, Douglas E.

“…Genes that are characteristic of only certain strains of a bacterial species can be of great biologic interest. Here we describe a PCR-based subtractive…”
Get full text

The role of MRI in understanding the underlying mechanisms in obesity associated diseases by Mitra, Sunanda, Fernandez-Del-Valle, Maria, Hill, Jason E.

“…Obesity and its possible association with diseases including diabetes and cardiovascular diseases have been studied for decades for its impact on healthcare…”
Get full text

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML by Pratz, Keith W, Cherry, Mohamad, Altman, Jessica K, Cooper, Brenda W, Podoltsev, Nikolai A, Cruz, Jose Carlos, Lin, Tara L, Schiller, Gary J, Jurcic, Joseph G, Asch, Adam, Wu, Ruishan, Hill, Jason E, Gill, Stanley C, James, Angela J, Rich, Elizabeth Shima, Hasabou, Nahla, Perl, Alexander E, Levis, Mark J

“…Gilteritinib is a type 1 FLT3 inhibitor active as monotherapy for relapsed or refractory -mutated AML. We investigated the safety, tolerability, and efficacy…”
Get full text

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations by Tarver, Theodore C., Hill, Jason E., Rahmat, Leena, Perl, Alexander E., Bahceci, Erkut, Mori, Kenichi, Smith, Catherine C.

“…Gilteritinib is the first FMS-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitor (TKI) approved as monotherapy in acute myeloid leukemia with FLT3…”
Get full text

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy by Wang, Eunice S., Montesinos, Pau, Minden, Mark D., Lee, Je-Hwan, Heuser, Michael, Naoe, Tomoki, Chou, Wen-Chien, Laribi, Kamel, Esteve, Jordi, Altman, Jessica K., Havelange, Violaine, Watson, Anne-Marie, Gambacorti-Passerini, Carlo, Patkowska, Elzbieta, Liu, Shufang, Wu, Ruishan, Philipose, Nisha, Hill, Jason E., Gill, Stanley C., Rich, Elizabeth Shima, Tiu, Ramon V.

“…•In patients with FLT3mut+ AML unfit for intensive chemotherapy, CRc rate was higher with GIL + AZA than with AZA.•OS was not significantly different between…”
Get full text

Stress-induced secretion of growth inhibitors : a novel tumor suppressor function of p53 by KOMAROVA, E. A, DIATCHENKO, L, ROKHLIN, O. W, HILL, J. E, WANG, Z. J, KRIVOKRYSENKO, V. I, FEINSTEIN, E, GUDKOV, A. V

“…p53 tumor suppressor gene controls cell response to a variety of stresses inducing growth arrest or apoptosis in damaged cells. It largely determines the…”
Get full text

Lisette Model's Explanation: Ralph Steiner, PM, and the Journalistic Frame by Hill, J. E.

Get full text

Training a Sensibility: Notes on American Art and Mass Media by Hill, Jason E., Schaar, Elisa

“…With Bernice Abbot's 1932 exhibition of "Murals by American painters and photographers" at the Museum of Modern Art in New York City, she broached the problem…”
Get full text

Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice by BURDELYA, Lyudmila G, KOMAROVA, Elena A, HILL, Jason E, BROWDER, Timothy, TARAROVA, Natalia D, MAVRAKIS, Lori, DICORLETO, Paul E, FOLKMAN, Judah, GUDKOV, Andrei V

“…Inactivation of p53 function, which frequently occurs in tumors, can significantly modulate tumor cell sensitivity to radiation and chemotherapeutic drugs…”
Get full text

Impact of FLT3 Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial by Wang, Eunice S., Altman, Jessica K., Minden, Mark D., Wu, Ruishan, Rich, Elizabeth Shima, Hill, Jason E.

“…▪ Background: The presence of measurable residual disease (MRD) after achievement of remission with induction therapy is a prognostic marker of relapse risk in…”
Get full text

A Phase 1, Dose-Escalation Study of Gilteritinib Combined with Chemotherapy in Patients Aged 6 Months to <21 Years with FLT3 Internal Tandem Duplication-Positive Relapsed or Refractory AML by Connor, Philip, Fan, Linyi, Gill, Stanley, Hill, Jason E., Philipose, Nisha, Delgado, David, Tiu, Ramon V., Reinhardt, Dirk

“…Background: Acute myeloid leukemia (AML) accounts for ~18% of all childhood leukemias (Puumala SE, et al. Pediatr Blood Cancer. 2013;60(5):728-733)…”
Get full text

How to Look at News Pictures in America by Hill, Jason E.

Get full text

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy by Wang, Eunice S., Montesinos, Pau, Minden, Mark D., Lee, Je-Hwan, Heuser, Michael, Naoe, Tomoki, Chou, Wen-Chien, Laribi, Kamel, Esteve, Jordi, Altman, Jessica K., Havelange, Violaine, Watson, Anne-Marie, Gambacorti-Passerini, Carlo, Patkowska, Elzbieta, Liu, Shufang, Wu, Ruishan, Philipose, Nisha, Hill, Jason E., Gill, Stanley C., Rich, Elizabeth Shima, Tiu, Ramon V.

“…Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated (FLT3mut+) acute myeloid leukemia (AML) ineligible for intensive…”
Get full text